Formulary
Deutivacaftor with tezacaftor and vanzacaftor: Indications, Dosing, Side Effects and Interactions
Deutivacaftor with tezacaftor and vanzacaftor clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Deutivacaftor with tezacaftor and vanzacaftor: Indications, Dosing, Side Effects and Interactions
Deutivacaftor with tezacaftor and vanzacaftor clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Cystic fibrosis [using tablets containing 125/50/10 mg deutivacaftor/tezacaftor/vanzacaftor] (specialist use only)**
- **Adult** (By Mouth): 2 tablets once daily.
**Cystic fibrosis [using tablets containing 50/20/4 mg deutivacaftor/tezacaftor/vanzacaftor] (specialist use only) for deutivacaftor with tezacaftor and vanzacaftor**
- **Child 6-11 years (body-weight up to 40 kg)** (By mouth): 3 tablets once daily.
**Cystic fibrosis [using tablets containing 125/50/10 mg deutivacaftor/tezacaftor/vanzacaftor] (specialist use only) for deutivacaftor with tezacaftor and vanzacaftor**
- **Child 6-11 years (body-weight 40 kg and above)** (By mouth): 2 tablets once daily.
- **Child 12-17 years** (By mouth): 2 tablets once daily.
Side effects
For deutivacaftor with tezacaftor and vanzacaftor Common or very common Diarrhoea; headache; rash Side-effects, further information Manufacturer advises interrupt treatment if transaminase levels more than 5 times the upper limit of normal or transaminase levels more than 3 times the upper limit of normal and blood bilirubin more than twice the upper limit of normal-consult product literature.
Pregnancy
For deutivacaftor with tezacaftor and vanzacaftor Avoid unless potential benefit outweighs risk (limited information available). M
Breast feeding
For deutivacaftor with tezacaftor and vanzacaftor Avoid (present in milk in animal studies). M
Hepatic impairment
For deutivacaftor with tezacaftor and vanzacaftor Avoid in severe impairment; use with caution only if benefit outweighs risk in moderate impairment (limited information available). M
Renal impairment
For deutivacaftor with tezacaftor and vanzacaftor Use with caution in severe impairment or end-stage renal disease (no information available). M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Deutivacaftor with tezacaftor and vanzacaftor in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

